Pulmonary hypertension (PH), particularly pulmonary arterial hypertension (PAH), is a rare but life-threatening disorder. Commercial interest in PH/PAH has increased recently due to significant advances in the understanding of its etiology and pathophysiology, and the emergence of new therapies to treat it. Despite the relatively small patient population in the major pharmaceutical markets, the PAH therapy market is a billion-dollar market that is expected to increase over the coming decade. Our new Current Treatment content provides deep insights into the current treatment of PH/PAH in the United States, and the factors behind those treatment decisions.
- What impact have the launches of novel therapies such as Uptravi, Orenitram, and Adempas, had on prescribing behavior for PH and PAH?
- What influence has the positive Phase III AMBITION trial, evaluating the upfront dual combination therapy of Letairis and Adcirca, had on the treatment algorithm for PAH?
- How are specialists utilizing PAH therapies for the treatment of PHWHO groups 2-5?
- What factors and drug therapy attributes are driving prescribing behavior for the treatment of PAH/PH?
Markets covered: United States
Methodology: Surveys of 51 cardiologists and 53 pulmonologists in the United States, completed in January 2017.
Indication coverage: Pulmonary Hypertension (PH) and Pulmonary Arterial Hypertension (PAH).
Key drugs covered: Uptravi, Orenitram, Adempas, Opsumit, Letairis, Adcirca, Bosentan, Revatio, Tyvaso, Remodulin, Veletri, Flolan.
Key companies mentioned: Actelion, Bayer, Gilead, GlaxoSmithKline, United Therapeutics.